NCT00509665View on ClinicalTrials.gov

Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions
Head and Neck Cancer
Interventions
DRUG

doxorubicin hydrochloride

given as 25mgm2 IV on days 1 and 8 of each 21-day cycle.

DRUG

gemcitabine hydrochloride

given as 100mg/m2 IV over days 1 and 8 of each 21 day cycle

Trial Locations (1)

29425

Hollings Cancer Center at Medical University of South Carolina, Charleston

All Listed Sponsors
lead

Medical University of South Carolina

OTHER

NCT00509665 - Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer | Biotech Hunter | Biotech Hunter